ASH 2020 | CARTITUDE-1: latest data & CRS in myeloma treated with cilta-cel
Ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on CARTITUDE-1 (NCT03548207), a study which investigated the use of cilta-cel in relapsed/refractory (R/R) multiple myeloma and highlights cytokine release syndrome (CRS) in those treated. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultant: Kite/Gilead, Celgene/BMS, JUNO/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite
Grant/Research Support: Kite/Gilead, Celgene, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda, Boston Scientific
Data safety monitoring board: Sorrento
All funds paid to Mayo Clinic, no personal compensation.
